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Background
The INTEGRATE study investigates the effectiveness
and cost-effectiveness of a “Personalized Prevention
Approach for Cardiometabolic risk” (PPA CMR). This is
a combination of an online risk estimation as used in
the Dutch guideline ‘the Prevention consultation’ (Dutch
PC-guideline) [1] and a tailored lifestyle intervention.




The first interim analysis in October 2014 in 11 prac-
tices showed expected response rates of 40 % on the first
step. However, the results of the online risk estimation
(step 2) were different than expected. Only 27 % of the
participants had a score above threshold and was eligible
for the third step. This is far less than the 60 % that we
had expected, based on results of the pilot study in 2009
[3]. As a consequence, only half of the expected partici-
pants proceeds to step 3 of the intervention (additional
measurements).
Risk estimation
The explanation for the difference between the findings
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gorithm used in the 2009 pilot study. According to in-
formation provided by the guideline team of Dutch
College of GPs, responsible for the guideline, the risk
score calculation was reassessed before publication in
the Dutch PC-guideline.
The assumptions made for the sample size calculation
for the INTEGRATE study are based on the results of
the risk score calculation in the pilot study.
The guideline authors and the INTEGRATE research
team conclude that there is a chance that the risk score
calculation as used in the INTEGRATE study could lead
to a number of misclassified participants at moderate
risk for cardiometabolic diseases (CMD) who score
under the threshold. To study this, we have decided to
adapt the study protocol.
Amendment in protocol
In addition to our published protocol we will perform
additional measurements in a selection of participants
with scores below threshold in April and June 2016. We
will invite this group for the same intervention as the
participants with a score above threshold.
Criteria for inviting people for additional measure-
ments will be participants with one of the following risk
factors for CMD:
– a family history of cardiovascular disease
– BMI >27
– smokers aged 50 and older
The results will show the number of newly detected
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in what range the risk estimation is most (cost-) effective.
Based on these results we will be able to give advice
whether to reassess the threshold of the risk score in the
Dutch PC guideline.
Consequences
– The aim of the study remains unchanged: “the
effectiveness and cost-effectiveness of a cardiometa-
bolic risk assessment and treatment program inte-
grated in primary care”.
– The sample size calculation is no longer applicable.
The intervention group will be smaller than
expected in the original protocol. This has
consequences for the power of the study. The study
might not have sufficient power to detect a
difference in the number of smokers. However, the
study will have sufficient power to detect differences
in the other CMD risk factors such as BMI and
blood pressure.
– The cost-effectiveness analysis will be performed ac-
cording to plan
– Additional measurements will be performed in the
last two groups of study participants in April and
June 2016 (eligible participants n = 10.000) with risk
scores below threshold and aforementioned risk
factors for CMD.
Ethics and funding bodies
The described amendment in our protocol was approved
by the UMC Utrecht Institutional Review Board and
exempted from full assessment under the Medical Re-
search involving human subjects Act.
We have received additional funding by ZonMw (The
Netherlands organization for Health Research and devel-
opment), Lekker Lang Leven (a collaboration of the
Dutch Diabetes Research Foundation, the Dutch Heart
Foundation and the Dutch Kidney foundation) and
Innovatiefonds Zorgverzekeraars (Healthcare Insurance
Innovation Fund) to compensate for the 6 month delay
and the costs for the additional measurements. The
Dutch College of GPs who developed the Dutch PC-
guideline fully supports the amendment made in our
protocol.
Conclusion
The amendment in the protocol is in our opinion the
best solution to guarantee the validity of the INTE-
GRATE study. The aim of our study remains unchanged.
However, the amendment will enable us to establish the
optimal and most cost-effective threshold for the online
risk estimation. Furthermore it gives us the opportunityto advice the Dutch College of GP’s how to improve the
Dutch PC-guideline.
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